Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (EWTX) is a clinical-stage biopharmaceutical company pioneering orally administered therapies for severe musculoskeletal disorders. This page serves as the definitive source for verified corporate announcements, clinical development updates, and strategic business developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated news collection provides essential insights into the company's work on dystrophinopathy treatments like Sevasemten and EDG-7500.
Key categories include quarterly financial results, research collaborations, FDA communications, and scientific conference presentations. All content is rigorously verified to ensure accuracy and relevance for investment research purposes.
Bookmark this page for streamlined access to Edgewise Therapeutics' latest developments in neuromuscular treatment innovation. Check regularly for real-time updates on this clinical-stage biopharma leader's progress.
Edgewise Therapeutics (NASDAQ: EWTX) has announced the pricing of an underwritten offering of 9,935,419 shares of common stock at $20.13 per share, expecting to raise approximately $200 million in gross proceeds. The offering, set to close on April 3, 2025, features participation from notable investors including Braidwell LP, Cormorant Asset Management, and OrbiMed.
The net proceeds will support the potential U.S. commercial launch of sevasemten for Becker muscular dystrophy patients, advance Phase 3 trials for sevasemten in Duchenne muscular dystrophy, and fund Phase 3 trials of EDG-7500 in patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The offering is being managed by Leerink Partners, Piper Sandler, Guggenheim Securities, and Truist Securities as joint book-running managers.
Edgewise Therapeutics (EWTX) announced positive top-line results from its Phase 2 CIRRUS-HCM four-week trial of EDG-7500 in patients with Hypertrophic Cardiomyopathy (HCM). The trial demonstrated significant efficacy in both obstructive and nonobstructive HCM patients.
Key findings for obstructive HCM patients at 100mg dose include:
- 71% reduction in resting LVOT gradients
- 58% reduction in provokable gradients
- 62% reduction in NT-proBNP heart failure biomarker
- 78% of participants improved by ≥1 NYHA Class
For nonobstructive HCM patients, the 100mg dose achieved a 42% reduction in NT-proBNP. The drug was generally well-tolerated, with most adverse events being mild to moderate. The company plans to initiate Phase 3 trials in the first half of 2026.
Edgewise Therapeutics (NASDAQ: EWTX) has announced a webcast event scheduled for April 2, 2025, at 8:30 am ET to present top-line results from their Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with hypertrophic cardiomyopathy (HCM). The 28-day trial evaluated EDG-7500 in both obstructive and nonobstructive HCM patients.
The webcast will feature presentations from the management team alongside two CIRRUS-HCM investigators, described as world leaders in HCM patient care. The event will include an accompanying slide presentation, with registration available through the Edgewise events page.
Edgewise Therapeutics (Nasdaq: EWTX) will present data on sevasemten, their first-in-class oral fast skeletal myosin inhibitor for Becker muscular dystrophy (BMD), at the MDA Clinical and Scientific Conference in Dallas from March 16-19, 2025.
The company will host an Industry Forum featuring Dr. Craig M. McDonald and Michael Voto, Jr. discussing BMD patient experiences and clinical advancements. Dr. McDonald will present the CANYON trial results showing sevasemten's effectiveness in reducing muscle damage biomarkers and stabilizing function in BMD patients.
The presentation includes five scientific posters covering:
- North Star Ambulatory Assessment predictions in BMD
- Two-year sevasemten treatment outcomes
- BMD skeletal phenotype analysis
- EDG-4131 myosin inhibitor results in BMD model mice
- Sevasemten's impact on muscle injury markers in the CANYON Phase II trial
Edgewise Therapeutics (Nasdaq: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation at the Leerink Partners Global Healthcare Conference. The presentation is scheduled for Tuesday, March 11, 2025, at 1:40 pm ET.
The event will feature a live webcast accessible through the Edgewise Events & Presentations page. Viewers are advised to connect several minutes before the start time to ensure proper connection. The presentation recording will be available for -time replay after the conference.
Edgewise Therapeutics (NASDAQ: EWTX) reported its Q4 and full year 2024 financial results, highlighting significant progress in its muscular dystrophy and cardiovascular portfolio. The company completed enrollment for the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy, with 175 adults across 51 sites in 12 countries.
Key financial metrics for Q4 2024 include:
- Cash position of $470.2 million
- R&D expenses of $36.4 million (up $4.2M from previous quarter)
- G&A expenses of $9.2 million
- Net loss of $39.7 million ($0.42 per share)
The company announced positive Phase 2 CANYON trial results and expects to report data from multiple ongoing trials in 2025, including: CIRRUS-HCM trial of EDG-7500 in Q1 2025, and Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy in H1 2025. GRAND CANYON study data is expected in Q4 2026.
Edgewise Therapeutics (NASDAQ: EWTX) announced key leadership changes to support its late-stage clinical development initiatives. Robert Blaustein, M.D., Ph.D. has been appointed as Chief Development Officer (CDO), bringing extensive cardiovascular drug development experience from Merck, where he led the successful development and approval of vericiguat for heart failure treatment. Behrad Derakhshan, Ph.D. has been promoted from Chief Business Officer to Chief Operating Officer (COO).
The company recently reported positive topline data from EDG-7500's Phase 1 trial in healthy subjects and the single-dose arm (part A) of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). The company has begun enrolling patients in the 28-day arms (parts B and C) and 12-week open label extension (part D) of the CIRRUS-HCM trial for both obstructive and non-obstructive HCM patients.
Edgewise Therapeutics (NASDAQ: EWTX) provided corporate updates and priorities for 2025, highlighting progress in their muscular dystrophy and cardiovascular programs. The company's lead drug sevasemten, a first-in-class fast skeletal myosin inhibitor for Becker and Duchenne muscular dystrophies, is nearing completion of pivotal cohort enrollment. The company plans to seek FDA feedback on Phase 2 results in first half 2025.
For their cardiovascular program, EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM), will report initial 28-day data in Q1 2025 and 12-week trial results in H2 2025. Key 2024 achievements include raising $232 million through a public offering, positive Phase 2 CANYON trial results for Becker muscular dystrophy, and positive Phase 1 results for EDG-7500 in HCM patients.
Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation will be led by Kevin Koch, Ph.D., President and CEO, and is scheduled for 1:30 pm PT (4:30 pm ET). Key updates will cover the company's cardiovascular and muscular dystrophy programs and outline 2025 milestones. The presentation will be webcast live, and a replay will be available for a time on the Edgewise Events & Presentations page. Attendees are advised to connect several minutes early to ensure a timely connection.
Edgewise Therapeutics (NASDAQ: EWTX) announced positive topline results from its Phase 2 CANYON trial of sevasemten in Becker muscular dystrophy patients. The trial met its primary endpoint with a significant 28% reduction in creatine kinase levels, a biomarker of muscle damage. The key secondary endpoint showed stabilization in North Star Ambulatory Assessment (NSAA) scores, with a trend toward improvement compared to placebo.
The study, involving 40 adults and 29 adolescents, demonstrated sevasemten was well-tolerated with no new safety concerns. Additional functional measures showed positive trends, and 99% of eligible participants enrolled in the MESA open-label extension trial. The company plans to complete recruitment for the GRAND CANYON pivotal cohort by Q1 2025 and will engage with FDA and EMA regarding marketing authorization strategies.
